Servier acquires Pixuvri from CTI BioPharma
The treatment was approved for use in the European Union in June this year.
Read More
Tag: Pixuvri
Pixuvri approved for use in EU
The drug has been granted the conversion of the conditional approval into standard marketing authorisation as a single agent.
Read More
CTI, Servier’s Pixuvri fails in post-marketing trial
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche’s MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
